TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23139262

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin (50 mg/m² d1), ifosfamide (3 g/m²/day d1-2), cisplatin (75 mg/m² d3) + G-CSF every 3 weeks (arm A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm B)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin, ifosfamide, cisplatin + G-CSF (arm A)
Number of subjects: 81
Study: 22256637

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong capsule
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Western medication
Number of subjects: 320
Study: 18438705

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg for 14 days)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg for 14 days)
Number of subjects: 206
Study: 17069753

Group type: EXPERIMENTAL
Intervention: CBT focused solely on panic disorder and agoraphobia
Number of subjects: 65

Group type: COMPARATOR
Intervention: CBT that addressed panic disorder and comorbid conditions
Number of subjects: 65
Study: 14679377

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) diet with healthy eating advice (n=26, age 63.6+/‐9.4 y)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy eating dietary advice only (control group, n=29, age 61.8+/‐9 y)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (LGI diet and control diet)
Number of subjects: 55
Study: 11476130

Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Haloperidol 5 mg/day
Number of subjects: 54
Study: 9597411

Group type: EXPERIMENTAL
Intervention: Creatine 20 g daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8192458

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) at 30 mg/kg/day for 10 days
Number of subjects: 263

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (AMX-CL) at 40 mg/kg/day for 10 days
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (AMX-CL)
Number of subjects: 263
Study: 3285829

Group type: EXPERIMENTAL
Intervention: torasemide (20 mg i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: furosemide (40 mg i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 8
Study: 30676813

Group type: EXPERIMENTAL
Intervention: 10-min cold shower after running exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No shower (control trial)
Number of subjects: 10
Study: 28195544

Group type: EXPERIMENTAL
Intervention: New test statistics based on multinomial distributions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cochran test
Number of subjects: 0
Study: 26376926

Group type: EXPERIMENTAL
Intervention: Standard-dose trivalent subunit inactivated intramuscular vaccine
Number of subjects: 213
Study: 22862902

Group type: EXPERIMENTAL
Intervention: Lightweight large-pore mesh with human fibrin glue (HFG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard heavyweight small-pore mesh with human fibrin glue (HFG)
Number of subjects: 80
Study: 21335509

Group type: EXPERIMENTAL
Intervention: Tuberculosis
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Tuberculosis diagnosis
Number of subjects: 29133
Study: 19432601

Group type: EXPERIMENTAL
Intervention: Psychosocial support (companionship during labour)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 585
Study: 16918614

Group type: EXPERIMENTAL
Intervention: Glycerol ointment applied twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 14726725

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emergency hospitalization
Number of subjects: 0
Study: 11142582

Group type: EXPERIMENTAL
Intervention: Oral prednisone 0.2 mg/kg/day for 6 months (group A)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon 3 MU, three times a week for 6 months (group B)
Number of subjects: 13
Study: 9382659

Group type: EXPERIMENTAL
Intervention: Aspirin and antiplatelet agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulants (including warfarin sodium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers (including timolol maleate, propranolol hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (including captopril, ramipril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering (including simvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other interventions
Number of subjects: 0
Study: 8322563

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2% and adrenaline 1:200,000 with crystalloid volume loading of 10 ml.kg-1 b.w.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tetracaine 1%
Number of subjects: 20
Study: 2868656

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg twice daily for 10 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily for 10 weeks)
Number of subjects: 30
Study: 30789581

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 29986676

Group type: EXPERIMENTAL
Intervention: Obesity and diabetes intervention program (PASOS)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 600
Study: 27427558

Group type: EXPERIMENTAL
Intervention: Cariprazine (3, 6, or 9 mg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 24255008

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 1.5ATA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2.0ATA
Number of subjects: 61

Group type: COMPARATOR
Intervention: Surface air (sham)
Number of subjects: 61
Study: 23301475

Group type: EXPERIMENTAL
Intervention: Auricular point sticking with vaccaria seed at Endocrine (CO18), Mammary Gland, etc., pressed 3 times daily for 1-2 min each time
Number of subjects: 107

Group type: COMPARATOR
Intervention: Routine hospital care (Control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Auricular point sticking
Number of subjects: 107
Study: 20506356

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 176
Study: 18086500

Group type: EXPERIMENTAL
Intervention: Baby massage classes
Number of subjects: 65

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 65
Study: 16049131

Group type: EXPERIMENTAL
Intervention: Hospitalists
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 21
Study: 12621135

Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12775187

Group type: EXPERIMENTAL
Intervention: Amnesic participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: College participants
Number of subjects: 0
Study: 9652876

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 2607

Group type: COMPARATOR
Intervention: Control (not treated with nifedipine)
Number of subjects: 2607
Study: 7661158

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. and amoxicillin 1 g t.i.d. (OA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d., amoxicillin 1 g t.i.d. plus tetracycline 500 mg t.i.d. (OAT)
Number of subjects: 60
Study: 2508566

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin C (MMC) and tegafur (FT)
Number of subjects: 2477

Group type: COMPARATOR
Intervention: Surgical resection only
Number of subjects: 2477
Study: 813585

Group type: EXPERIMENTAL
Intervention: Carbohydrate TIN
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fat TIN (Intralipid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study: 29635383

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28712185

Group type: COMPARATOR
Intervention: Propofol alone (Group I)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg) + Propofol (Group II)
Number of subjects: 86
Study: 26647926

Group type: EXPERIMENTAL
Intervention: EFT+PCM (test group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CAF+PCM (control group)
Number of subjects: 20
Study: 24012096

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (6 mL)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 145
Study: 21794845

Group type: EXPERIMENTAL
Intervention: 0.05% AR‐12286 Ophthalmic Solution
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 0.1% AR‐12286 Ophthalmic Solution
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 0.25% AR‐12286 Ophthalmic Solution
Number of subjects: 89

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 89
Study: 19737493

Group type: EXPERIMENTAL
Intervention: Alcohol Dependence Scale (ADS)
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: Total ADS and subscales derived from factor analyses
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: 12-item reduced ADS measure
Number of subjects: 3001

Group type: EXPERIMENTAL
Intervention: 9-item reduced ADS measure
Number of subjects: 3001
Study: 16514567

Group type: EXPERIMENTAL
Intervention: Protein meal (2 meals rich in protein)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (1 meal rich in carbohydrates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fat meal (1 meal rich in fat)
Number of subjects: 8
Study: 15484172

Group type: EXPERIMENTAL
Intervention: Managerial-based intervention involving changes in nurses' skill discretion and decision-making participation over six months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study: 10688085

Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate (TUVP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 54
Study: 8996166

Group type: EXPERIMENTAL
Intervention: Direct inhibitor of TS (ZD1694)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect inhibitor (5-FU/LV)
Number of subjects: 0
Study: 8440808

Group type: EXPERIMENTAL
Intervention: Moclobemide treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reversed depressive symptoms
Number of subjects: 0
Study: 29053933

Group type: EXPERIMENTAL
Intervention: 50 mg ellagic acid daily for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo cellulose
Number of subjects: 150
Study: 26689303

Group type: EXPERIMENTAL
Intervention: Sleep-directed hypnosis for 3 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Symptom monitoring control condition for 3 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) after initial treatment
Number of subjects: 108
Study: 24716545

Group type: EXPERIMENTAL
Intervention: Semi-tailored facilitator-based intervention with three one-hour visits by a facilitator.
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Semi-tailored facilitator-based intervention.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Delayed intervention group (control).
Number of subjects: 189
Study: 22399019

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 12 sessions, manualized
Number of subjects: 369

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 369
Study: 20223272

Group type: EXPERIMENTAL
Intervention: Bioactive glass air-polishing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sodium bicarbonate air-polishing
Number of subjects: 50
Study: 18350566

Group type: EXPERIMENTAL
Intervention: 3 mg eszopiclone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 15699766

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 12006422

Group type: EXPERIMENTAL
Intervention: High-dose inhaled fluticasone propionate (FP), 2,000 microg/d for 8 weeks
Number of subjects: 9
Study: 10589605

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg IV
Number of subjects: 54
Study: 9082800

Group type: EXPERIMENTAL
Intervention: Microbipolar dissection (MBPD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cold knife dissection with suction cautery (CKC)
Number of subjects: 200
Study: 1745846

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: OM-85 BV (subgroup aged 6 years and less)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 6354932

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg three times daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril plus Nifedipine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30690554

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 3
Study: 29128183

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Non-intraoperative neuromonitoring
Number of subjects: 1328
Study: 27812649

Group type: EXPERIMENTAL
Intervention: Symbiotic product (Lactobacillus bulgaricus, Lactobacillus rhamnosus, and fructo‐oligosaccharides) administered twice a day for seven days via oral/enteral route
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Symbiotic product
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Symbiotic product and Placebo
Number of subjects: 116
Study: 24557492

Group type: EXPERIMENTAL
Intervention: Propranolol treatment (group 2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Prepropranolol treatment (group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nonpropranolol treatment (group 3)
Number of subjects: 58
Study: 22784344

Group type: EXPERIMENTAL
Intervention: TJ-15 plus TJ-17
Number of subjects: 24

Group type: COMPARATOR
Intervention: TJ-15
Number of subjects: 24
Study: 20830534

Group type: EXPERIMENTAL
Intervention: Amino acids starting within 24 h of birth, advanced to 2.5 g/kg per day by day 3
Number of subjects: 17

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 17
Study: 18190318

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 64

Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 64
Study: 15220202

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose at baseline
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Overweight individuals
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Dyslipidemia or hypertension
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Low insulin sensitivity and low insulin response
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: HOMA-IR and Sluiter's Index
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Baseline impaired fasting glucose, BMI, HOMA-IR, and Sluiter's Index
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Population-standardized incidence rate
Number of subjects: 837
Study: 12469360

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) treatment
Number of subjects: 285

Group type: COMPARATOR
Intervention: Insulin treatment (Control)
Number of subjects: 285
Study: 10099053

Group type: EXPERIMENTAL
Intervention: 10 mg ebastine (elderly)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 10 mg ebastine (young)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 10 mg ebastine (both groups)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Electrocardiography (both groups)
Number of subjects: 37
Study: 7806020

Group type: EXPERIMENTAL
Intervention: IDDM women with microalbuminuria
Number of subjects: 42

Group type: COMPARATOR
Intervention: IDDM women with normoalbuminuria
Number of subjects: 42
Study: 2594822

Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler
Number of subjects: 8

Group type: COMPARATOR
Intervention: Salbutamol via Rotahaler
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both terbutaline and salbutamol at highest dose
Number of subjects: 8
Study: 1100306

Group type: EXPERIMENTAL
Intervention: Prorenoate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 12
Study: 30831600

Group type: EXPERIMENTAL
Intervention: Serum ferritin <15 μg/L
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Serum soluble transferrin receptor (sTfR) >4.4 mg/L
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Calculated total body iron <0 mg/kg
Number of subjects: 792
Study: 29211949

Group type: EXPERIMENTAL
Intervention: Fluocaril® Bi‐Fluoré 250 (1500 ppm F as NaF+1000 ppm F as SMFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard toothpaste (1100 ppm as NaF/silica)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LacerAnticaries (2500 ppm F as SMFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elmex® Caries Professional™ (1450 ppm F as SMFP+1.5% arginine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate® Triple Action (1450 ppm F as SMFP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 0
Study: 27050997

Group type: EXPERIMENTAL
Intervention: GR‐α expression in tonsil tissues of OSAHS children
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GR‐β expression in tonsil tissues of OSAHS children
Number of subjects: 30
Study: 24805901

Group type: EXPERIMENTAL
Intervention: Online mediated social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective monitoring of physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured high‐intensity workouts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point‐of‐decision prompts
Number of subjects: 0
Study: 22801470

Group type: EXPERIMENTAL
Intervention: Forward head posture corrective exercise programme
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional treatment (stretching and strengthening exercises)
Number of subjects: 76
Study: 19439637

Group type: EXPERIMENTAL
Intervention: Marinated broiler breast fillets deboned pre-rigor with 1% salt and 0.45% phosphate
Number of subjects: 400

Group type: COMPARATOR
Intervention: Marinated broiler breast fillets deboned postrigor with 1% salt and 0.45% phosphate
Number of subjects: 400
Study: 17462541

Group type: EXPERIMENTAL
Intervention: 0.9% alcohol beer
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual alcohol intake
Number of subjects: 16
Study: 16496609

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (HT) with untreated essential hypertension
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Deletion alleles (D or 4G) in hypertensive patients
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Lipid disorders in hypertensive patients
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: ACE I/D and PAI‐1 4G/5G polymorphisms
Number of subjects: 147
Study: 12205547

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) 10 mg/24 hours adhesive patch
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 31
Study: 10542357

Group type: EXPERIMENTAL
Intervention: Slice adaptation method for cine velocity mapping
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spatially fixed slice method
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motion correction for patients with clinical aortic regurgitation
Number of subjects: 15
Study: 8547379

Group type: EXPERIMENTAL
Intervention: Comprehensive multidisciplinary geriatric assessment in an inpatient geriatric assessment unit (mean length of stay, 16.5 days)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Comprehensive multidisciplinary geriatric assessment in an inpatient geriatric assessment unit
Number of subjects: 312
Study: 2183868

Group type: COMPARATOR
Intervention: Atenolol (50‐100 mg once daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nitrendipine (20‐40 mg once daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Combination of atenolol (50 mg) and nitrendipine (20 mg) once daily
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 69
Study: 6258620

Group type: EXPERIMENTAL
Intervention: Isoprenaline given 30 min before paracetamol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Isoprenaline given immediately before paracetamol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propranolol given alone
Number of subjects: 35
Study: 31012497

Group type: EXPERIMENTAL
Intervention: 10 weeks of progressive vigorous‐intensity interval training performed three times per week
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (received tailored lifestyle recommendations)
Number of subjects: 77
Study: 27916338

Group type: EXPERIMENTAL
Intervention: Forearm band worn for more than 6 hours daily for at least 6 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-band group (control)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Forearm band
Number of subjects: 110